Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075698 | 0.81 | EPHX2 (0.39) | EPHX2GFER | |
| SCHEMBL15075715 | 0.79 | EPHX2 (0.35) | EPHX2GFER | |
| SCHEMBL4518207 | 0.78 | TSHR (0.38) | ALDH1A1TSHRAPEX1BLM | |
| SCHEMBL15384434 | 0.77 | ALDH1A1 (0.34) | ALDH1A1TP53SMN1; SMN2TSHRAPEX1 | |
| SCHEMBL18819656 | 0.77 | EPHX2 (0.35) | SMN1; SMN2EPHX2GFER | |
| SCHEMBL18819094 | 0.75 | EPHX2 (0.34) | ALDH1A1SMN1; SMN2EPHX2GFER | |
| SCHEMBL19036662 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TP53SMN1; SMN2TSHREPHX2 | |
| SCHEMBL18819443 | 0.73 | EPHX2 (0.41) | ALDH1A1EPHX2HPGDHSD17B10GFER | |
| SCHEMBL15384407 | 0.72 | TSHR (0.40) | TSHRAPEX1BLM | |
| SCHEMBL18819722 | 0.68 | EPHX2 (0.37) | ALDH1A1EPHX2HPGDHSD17B10GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016044792-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20130165427-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165427-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885TP53 1505/4885SMN1; SMN2 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.